These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18685357)

  • 21. C-reactive protein in urologic cancers.
    Huang J; Baum Y; Alemozaffar M; Ogan K; Harris W; Kucuk O; Master VA
    Mol Aspects Med; 2015 Nov; 45():28-36. PubMed ID: 25936279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications of artificial intelligence in urologic oncology.
    Pak S; Park SG; Park J; Cho ST; Lee YG; Ahn H
    Investig Clin Urol; 2024 May; 65(3):202-216. PubMed ID: 38714511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Optimizing treatment of advanced urologic malignancies].
    Heidenreich A; Ohlmann CH; Ozgür E; Pfister D; Sahi D; Thüer D; Engelmann UH
    Urologe A; 2007 Sep; 46(9):1278-84. PubMed ID: 17628781
    [No Abstract]   [Full Text] [Related]  

  • 24. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long noncoding RNA in prostate, bladder, and kidney cancer.
    Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
    Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications of spectroscopy in diagnosis, staging, and treatment of urologic malignancies.
    Seltz LM; Herrell SD
    Curr Opin Urol; 2016 May; 26(3):259-63. PubMed ID: 26914060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.
    Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Bianchi M; Boorjian SA; Sun M; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2014 Mar; 65(3):554-62. PubMed ID: 24094576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.
    Ruiz de Porras V; Font A
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric urologic oncology.
    Kramer SA
    Urol Clin North Am; 1985 Feb; 12(1):31-42. PubMed ID: 2983474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next revolution in molecular theranostics: personalized medicine for urologic cancers.
    Aoun F; Kourie HR; Artigas C; Roumeguère T
    Future Oncol; 2015; 11(15):2205-19. PubMed ID: 26235183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highlights from the Society of Urologic Oncology, 5th Annual Meeting, December 3-4, 2004, Bethesda, Maryland, United States of America.
    Grubb RL; Behari A; Kim CM; Williams CR; Linehan WM; Coleman JA
    J Urol; 2005 Dec; 174(6):2330-3. PubMed ID: 16280834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular diagnostics in urologic oncology. Detection of nucleic acids in urine samples].
    Müller M; Goessl C; Krause H; Miller K
    Urologe A; 2003 May; 42(5):660-8. PubMed ID: 12750801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
    Tonyali S; Yazici S
    Int Urol Nephrol; 2016 May; 48(5):671-80. PubMed ID: 26843415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "mirage"?
    Netto GJ
    Adv Anat Pathol; 2013 May; 20(3):175-203. PubMed ID: 23574774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis, therapy and prognosis of urologic tumors in the aged].
    Guddat HM
    Z Alternsforsch; 1985; 40(3):155-7. PubMed ID: 4013373
    [No Abstract]   [Full Text] [Related]  

  • 36. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.
    Coen JJ; Paly JJ; Niemierko A; Kaufman DS; Heney NM; Spiegel DY; Efstathiou JA; Zietman AL; Shipley WU
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):311-6. PubMed ID: 23474117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tumor markers in urological malignancies].
    Kuriyama M
    Nihon Rinsho; 1996 Jun; 54(6):1631-6. PubMed ID: 8691621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Urologic tumors in old age].
    Debruyne FM
    Tijdschr Gerontol Geriatr; 1986 Apr; 17(2):65-8. PubMed ID: 3715964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.
    Raymond E; O'Callaghan ME; Campbell J; Vincent AD; Beckmann K; Roder D; Evans S; McNeil J; Millar J; Zalcberg J; Borg M; Moretti K
    Radiat Oncol; 2017 Mar; 12(1):56. PubMed ID: 28327203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting.
    Drouin SJ; Yates DR; Hupertan V; Cussenot O; Rouprêt M
    World J Urol; 2013 Feb; 31(1):109-16. PubMed ID: 23247822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.